IL-3z WT CAR CIK cells

IL-3z WT CAR CIK cells are an experimental adoptive cell therapy being investigated for the treatment of acute myeloid leukemia (AML). This therapy utilizes cytokine-induced killer (CIK) cells—effector T lymphocytes with natural killer (NK) features—genetically engineered to express a first-generation chimeric antigen receptor (CAR) known as an IL-3-zetakine. The CAR construct incorporates the wild-type (WT) interleukin-3 (IL-3) ligand as the antigen-binding domain, which targets the IL-3 receptor alpha (CD123) overexpressed on AML blasts and leukemic stem cells. The signaling domain consists of the CD3ζ (zeta) chain. In preclinical research conducted by academic institutions such as the University of Perugia and University of Milano-Bicocca, these cells serve as a benchmark for high-affinity targeting, often compared against dual-CAR strategies or low-affinity mutant variants designed to reduce on-target/off-tumor toxicities against healthy CD123-expressing tissues like endothelial cells and hematopoietic stem cells.

Other names

IL-3-zetakine CAR CIK cellsIL3-zetakine CAR CIK cellsIL 3-zetakine CAR CIK cellsanti-CD123 IL-3z CAR CIK cellsanti-CD-123 IL-3z CAR CIK cellsanti-CD 123 IL-3z CAR CIK cellsWT IL-3z CAR CIK cells